All the news Showing 10 of 56 articles from: Genotype 1bGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Six weeks of sofosbuvir/ledipasvir cures genotype 1 acute hepatitis C in people without HIV Liz Highleyman / 30 November 2016 A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results ... Grazoprevir triple regimen demonstrates high cure rates, even for hard-to-treat people Liz Highleyman / 23 November 2016 A new three-drug co-formulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2 or 3, with sustained response rates ... AbbVie 3D regimen taken for 8 weeks cures almost all HCV genotype 1b patients without cirrhosis Liz Highleyman / 06 October 2016 AbbVie’s paritaprevir-based ‘3D’ regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat patients with hepatitis C virus (HCV) genotype 1b who did not have cirrhosis, ... Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... New Merck combination pill Zepatier approved for hepatitis C treatment in the United States Keith Alcorn / 01 February 2016 Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor) and elbasvir (an NS5A inhibitor) ... Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks Liz Highleyman / 02 December 2015 Response-guided therapy using an all-oral regimen of three direct-acting antivirals cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from the small SODAPI pilot study, ... New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study Keith Alcorn / 16 November 2015 A combination of two experimental direct-acting antivirals developed by AbbVie cured 97 to 100% of people without cirrhosis with genotype 1 hepatitis C infection in a mid-stage phase 2 study presented this ... Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3 Liz Highleyman / 16 November 2015 An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis C virus (HCV), including treatment-experienced people ... Paritaprevir and ombitasvir are effective for Japanese patients with HCV genotype 1b Keith Alcorn / 26 May 2015 Viekirax (ombitasvir and paritaprevir with ritonavir) was highly effective in curing hepatitis C without the accompaniment of dasabuvir (Exviera) in Japanese people with genotype 1b hepatitis C infection in the GIFT 1 trial, ... ← First12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive